Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis

Clinical trial NCT06173284 · COMPLETED

Trial details

NCT number: NCT06173284
Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Dermatitis, Atopic

Start date: 2024-01-22
Primary completion: 2025-09-26
Enrollment: 519

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.